

Present:

Ms L Green	Airedale NHS Trust
Ms D Parker	
Mrs V Allinson	Calderdale and Huddersfield NHS Foundation Trust
Ms S Booker	
Ms J Bottomley	
Ms J O'Brien	Harrogate and District NHS Foundation Trust
Ms K Lowe	Mid Yorkshire Hospitals NHS Trust
Ms L Newton (Chair)	
Mrs M Smith	
Mrs J Frazer	York Hospitals NHS Foundation Trust

Apologies

Mrs M Blackburn, Mrs J Davies, Mrs D Horsman, Mrs L Howard

2. Action Log from the last meeting			
Log No	Action	Lead(s)	Deadline
31	The Action Log from the last meeting was agreed as an accurate record.	N/A	N/A
3. Study Day			
Log No	Action	Lead(s)	Deadline
32	<p>The Group discussed the Study Day and agreed it was very good value for money, the venue was fine and the event evaluated very well. There was an overall problem with delegates not paying, but all outstanding payments have now been collected.</p> <p>There are still some Rep fees outstanding, when all payments have been received the day will have made a £400 profit.</p> <p>E Jehan to circulate the study day evaluation.</p>	E Jehan	20.02.09
33	<p>The Group discussed the next Study Day and L Newton asked for volunteers. Michele Smith, Julie Bottomley and Denise Parker have all put their names forward as they have experience, two new volunteers are needed. Ideas for the next Study Day are welcome.</p> <p>Two new volunteers needed for the next Study Day.</p>	All	Next Meeting
4. Patient Information Pathways			
Log No	Action	Lead(s)	Deadline
34	<p>V Allinson discussed the Patient Information Pathways, the Group agreed these are to be signed off as complete and there was some discussion as to whose responsibility it is to complete the pathway document. The Group also agreed the pathway needs to tie in with the overall Breast pathway and there is more work to be done.</p> <p>V Allinson to discuss at the next Breast NSSG.</p>	V Allinson	30.04.09

5. Presentation Update and New Products			
Log No	Action	Lead(s)	Deadline
35	<p>Deepak Dattani, Pfizer Rep presented to the Group on the Exemestane Study.</p> <p>Tamoxifen was the Gold Standard at York for 5 years. Trial looked at two/three year Tamoxifen switch to an A.I. Switching patients at two/three years shows definite improvement in disease free survival.</p> <p>Switching to Exemestane after two/three years reduces risk of dying by approximately 17%, serious side effects are rare.</p> <p>A document is needed to identify in the notes when to change to an Aromatase Inhibitor.</p> <p>D Dattani and Tracy to circulate a sample document for the Group to comment on.</p>	All	Next meeting
6. Secondary Disease Patient Pathway			
Log No	Action	Lead(s)	Deadline
36	<p>G Hughes discussed the Secondary Disease Patient Pathway, he stated that to develop services such as that proposed for secondary cancer that is imperative to influence the YCN Board and its constituent commissioning bodies (i.e. PCT's). To do this a pathway is required that describes the services required, it would then be necessary to asses the size of any resource gaps between the current and the proposed service. The Board/Commissioners could then decide whether or not to fund such a service.</p> <p>G Hughes to amend the second Breast Cancer Pathway and send to the Group for comments before the next Breast NSSG on 30th April 2009.</p> <p>V Allinson to take to the Breast NSSG and report back at the next meeting.</p>	G Hughes/V Allinson/All	30.04.09
7. Any Other Business			
Log No	Action	Lead(s)	Deadline
37	L Newton and T Cochrane are leaving their respective posts at Mid Yorkshire and Leeds and are joining the team at Bradford - congratulations to both.	N/A	N/A

Date of Next Meeting(s)

Thursday 30th April 2009 12:00pm
Pavilions of Harrogate, Great Yorkshire Showground, Harrogate